Biotech Values

[RNsidersbuying]

CBIO - today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash.

Why pay $60M cash for a corporation's asset when the entire market-cap of said corporation is less than $15M??? Kinda sure a valid business contract requires legitimate compensation from both parties!

https://docoh.com/filing/1124105/0001564590-22-018775/CBIO-10Q-2022Q1